Trials / NCT04945772
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Completed Phase 2 Optogenetics, Gene therapy
- Sponsor
- Nanoscope Therapeutics Inc.
- Treatment
- Gene Therapy Product-MCO-010; Sham Injection
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
- Ages
- 18 Years to no upper limit
- Enrollment
- 27 participants
- Started
- 2021-07-13
- Main results expected
- 2023-02-27
- Results posted
- Not yet
- Record last updated
- 2024-03-22
What the study is testing
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
Where it runs
Puerto Rico (1)
- Nanoscope Clinical Site, Arecibo
United States (5)
- Nanoscope Clinical Site, Beverly Hills, California
- Nanoscope Clinical Site, Pensacola, Florida
- Nanoscope Clinical Site, Fargo, North Dakota
- Nanoscope Clinical Site, Houston, Texas
- Nanoscope Clinical Site, McAllen, Texas